The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Job openings (Dec.) Factory orders (Dec.) Alphabet Inc (NASDAQ:GOOGL) (Q3) EPS for gain of $2.12, compared to $1.64 in the prior-year quarter. Toyota Motor Corporation (NYSE:TM) (Q3) EPS of $4.36, ...

Stocks rose on Thursday, posting gains in a bout of rocky trading as investors weighed the latest earnings from Big Tech companies. Stocks cut gains late in the session after President Donald Trump ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase ...

(You can read the full research report on Eli Lilly here >>>) Shares of Exxon ... a customer-centric approach, merchandise initiatives, and an emphasis on membership growth. These factors have ...